FIGURE 6.

A, survival of cells treated with GMX1778 in the absence or presence of 20 μm niacin. Conditions for the above are as follows: a, control; b, 20 μm niacin; c, GMX1778; d, GMX1778 + 20 μm niacin. The concentration of GMX1778 used for U251, U2OS, HCT116, and HCT116 p53^−/− cell lines was 5 nm. The breast cancer line MDA-MB-231 BR was treated with 15 nm and H1299 with 25 nm GMX11778. Immortalized breast cell MCF10A and normal breast cell HMEC were treated with 50 nm GMX1778. B, graph of percentage of colonies surviving in the presence of vehicle (DMSO), niacin, GMX1778, or GMX1778 with niacin. Concentrations are noted above and data is normalized to cells treated with vehicle.